Manfred Welslau, MD, discusses the interim results of the REFLECT trial in diffuse large B-cell lymphoma.
Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the interim results of the REFLECT trial in diffuse large B-cell lymphoma (DLBCL).
The REFLECT study is the first prospective post-approval trial evaluating the safety and efficacy of SDZ-RTX (Rixathon), a rituximab (Rituxan) biosimilar, in patients with untreated CD20-positive DLBCL.
As the field awaits the 24-month progression-free survival data, interim results from the study, presented during the 2020 ASCO Virtual Scientific Program, re-confirm the expected safety and efficacy profile of this biosimilar in patients with DLBCL.
Moreover, the overall response rate with SDZ-RTX was 88% with a complete response rate of 57% and partial response rate of 31%.
These real-world data do not suggest there are any significant differences between the biosimilar and the biologic, concludes Welslau.
